PLRX · Pliant Therapeutics, Inc.
Market Cap
$68.73M
Shares
61.92M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.11
Open$1.15
Day$1.11–1.15
52W close$1.03–1.87
Avg vol 30d444K
Short int2.8M · 4.5% float · 7.7d
Short vol52%
DataJun 2020–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+0%
above
RSI (14)
49
neutral
MACD trend
Positive
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
−16%
trailing
YTD return
−9%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.47% of float · ▼ -1.3% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
86 holders — near 3-yr low, contrarian setup
Squeeze score
61
elevated · 0–100
Fundamentals
EPS growth
+30%
Y/Y
Free cash flow
$-128.7M
Balance sheet
$45.4M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−45%
past year
ATR
4.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+0%
Bullish
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-5% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.47% of float · ▼ -1.3% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
86 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 10%
Range high $2
vs 200-day avg -10%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLRX
this stock
Pliant Therapeutics, Inc.
|
$68.73M | -9.0% | — | — | 4.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLRX | -3.9% | +6.7% | -15.9% | +6.7% | -9.0% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -4.4% | +3.7% | -29.3% | +3.7% | -21.8% |
Key facts
CIK
1746473
CUSIP
729139105
13F (30d)
85 filings
83 filers
Visit website
Investor relations